Influence of ADA (Adalimumab) on Fecal Calprotectin, QoL (Quality of Life) and Workability of Patients Suffering From Ulcerative Colitis (AdaProQuo)
Read time: 1 mins
Last updated:18th Mar 2014
The objectives of this study are to explore the effect of adalimumab on the fecal Calprotectin level of UC (Ulcerative Colitis) patients and the correlation with their general well-being (QoL), work ability and disease activity.
|Study start date||2014-03-18|